Clinical Commander

Back to dossier
endo.prolactinoma.core.v1PRODUCTION
endo.prolactinoma.core.v1

Prolactinoma and hyperprolactinemia

endocrinologychronicadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Hyperprolactinemia is a finding, not a diagnosis: exclude physiologic / drug / hypothyroid / renal-hepatic / macroprolactin / hook BEFORE naming a prolactinoma (Endo Soc 2011)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Confirmed true hyperprolactinemia framed against the exclusion ladder

Patient inputs (14)

Presentation and tumour-size distribution differ markedly by sex (women micro/early; men macro/late)

Premenopausal vs postmenopausal changes symptom salience and treatment goals; reproductive intent

Pregnancy is the leading physiologic cause AND drives DA choice/continuation (bromocriptine if conception planned)

Antipsychotics (risperidone/paliperidone), metoclopramide, SSRIs, verapamil, opioids, estrogens — the cardinal pharmacologic exclusion

Core analyte; magnitude triages stalk effect vs micro vs macroprolactinoma (>250 ng/mL favours macroprolactinoma)

Primary hypothyroidism raises TRH → PRL; reversible secondary cause to exclude before imaging

Pregnancy — the single most common physiologic cause; exclude first in any reproductive-age woman

CKD reduces PRL clearance (systemic cause); also informs MRI contrast safety

LH/FSH/estradiol/testosterone — confirm hypogonadism and gauge bone-loss risk if untreated

Hook-effect exclusion — 1:100 serial dilution when large sellar mass with only mild PRL elevation

PEG precipitation / macroprolactin screen when high PRL but asymptomatic (assay artifact)

Dedicated sellar MRI defines micro (<10 mm) vs macroadenoma and mass effect once secondary causes excluded

Macroadenoma abutting/compressing chiasm requires formal perimetry (bitemporal hemianopia)

Cirrhosis is a systemic cause of mild hyperprolactinemia

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningmacroadenoma_apoplexy_acute_visual_loss
    Macroprolactinoma with acute severe headache + acute visual loss / ophthalmoplegia (pituitary apoplexy) (Pituitary Soc 2023)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcsf_rhinorrhea_on_da_shrinkage
    CSF rhinorrhoea after dopamine-agonist-induced rapid macroadenoma shrinkage (Pituitary Soc 2023)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_da_impulse_control_or_psychosis
    Severe dopamine-agonist impulse-control disorder (pathological gambling/hypersexuality) or new psychosis (Endo Soc 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveregiant_mass_mild_prl_hook_effect
    Large/giant sellar mass with only mildly elevated prolactin — suspect HOOK EFFECT (Pituitary Soc 2023)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererapidly_progressive_visual_field_loss
    Macroadenoma with rapidly progressive bitemporal visual field loss without frank apoplexy (Pituitary Soc 2023)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatesymptomatic_hypogonadism_bone_loss
    Persistent hypogonadism with galactorrhoea / infertility / low bone density on untreated or sub-optimally treated hyperprolactinemia (Endo Soc 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSoptionalDrives severity classification
Loading…

Recommended regimen

Hyperprolactinemia exclusion → dopamine agonist → surgery → pregnancy → bone protection (Endo Soc 2011; Pituitary Soc 2023)
axis: prolactinoma_da_first_line_ladderstep 1 - Step 1 — Exclude/treat secondary causes & artifact (no prolactinoma drug yet)
Selected step "Step 1 — Exclude/treat secondary causes & artifact (no prolactinoma drug yet)" — Any elevated serum prolactin before labelling a prolactinoma
  • discontinue or substitute offending medication
    first line
    medication_reconciliation
    triggers: drug_induced_hyperprolactinemia, risperidone_or_metoclopramide, psychiatry_clearance_to_switch
    Stop/switch the culprit when psychiatrically safe; recheck PRL after the appropriate washout (Endo Soc 2011)
  • macroprolactin (PEG) screen
    first line
    assay_artifact_exclusion
    triggers: asymptomatic_high_prl
    Macroprolactin is biologically inert — avoids unnecessary imaging/treatment (Endo Soc 2011)
  • serial 1:100 prolactin dilution
    first line
    assay_artifact_exclusion
    triggers: large_sellar_mass_with_mild_prl
    Unmasks the HOOK EFFECT — falsely low PRL in a giant prolactinoma (Pituitary Soc 2023)
  • levothyroxine
    comorbidity specific
    thyroid_hormone
    weight-based replacement, titrate to TSH • PO • once daily
    triggers: primary_hypothyroidism
    Treating primary hypothyroidism removes the TRH drive and can normalise PRL (Endo Soc 2011)
    rxcui 10582

outpatient playbook — drug actions (4)

  1. 1. discontinue/substitute offending drug or treat hypothyroidism
    per culprit; levothyroxine titrated to TSH • PO • as indicated
    trigger: Secondary cause identified
    Treat the reversible cause before labelling a prolactinoma (Endo Soc 2011)
  2. 2. cabergoline
    0.25–0.5 mg twice weekly, titrate • PO • twice weekly
    trigger: Symptomatic micro/macroprolactinoma after exclusions
    Preferred first-line DA — normalises PRL, shrinks tumour, restores gonadal axis (Pituitary Soc 2023)
  3. 3. bromocriptine
    1.25 mg qHS, titrate to 2.5–7.5 mg/day • PO • daily–TID
    trigger: Pregnancy planned or cabergoline-intolerant
    Most pregnancy safety data (Endo Soc 2011)
  4. 4. estrogen/progestin or testosterone
    physiologic replacement • PO/transdermal/IM • per regimen
    trigger: Persistent hypogonadism or observed microadenoma
    Bone and gonadal protection if DA not used/effective (Endo Soc 2011)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Woman: galactorrhoea + oligo/amenorrhoea + infertility (Endo Soc 2011); Man: low libido / ED / infertility / gynecomastia (Pituitary Soc 2023); Incidental / screening elevated serum prolactin (Endo Soc 2011).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Prolactinoma and hyperprolactinemia** (endo.prolactinoma.core.v1).
Phenotype framing: Microprolactinoma vs macroprolactinoma vs stalk-effect mild hyperprolactinemia from a non-lactotroph mass (NFPA, craniopharyngioma, meningioma, metastasis) vs drug-induced vs primary hypothyroidism vs macroprolactin artifact vs idiopathic; co-secreting somatomammotroph (acromegaly + hyperprolactinemia)
Scope: Hyperprolactinemia is a finding, not a diagnosis: exclude physiologic / drug / hypothyroid / renal-hepatic / macroprolactin / hook BEFORE naming a prolactinoma (Endo Soc 2011)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Hyperprolactinemia exclusion → dopamine agonist → surgery → pregnancy → bone protection (Endo Soc 2011; Pituitary Soc 2023)** — step "Step 1 — Exclude/treat secondary causes & artifact (no prolactinoma drug yet)".
1. discontinue or substitute offending medication (medication_reconciliation, first line) — Stop/switch the culprit when psychiatrically safe; recheck PRL after the appropriate washout (Endo Soc 2011)
2. macroprolactin (PEG) screen (assay_artifact_exclusion, first line) — Macroprolactin is biologically inert — avoids unnecessary imaging/treatment (Endo Soc 2011)
3. serial 1:100 prolactin dilution (assay_artifact_exclusion, first line) — Unmasks the HOOK EFFECT — falsely low PRL in a giant prolactinoma (Pituitary Soc 2023)
4. levothyroxine weight-based replacement, titrate to TSH PO once daily (thyroid_hormone, comorbidity specific) — Treating primary hypothyroidism removes the TRH drive and can normalise PRL (Endo Soc 2011)

Setting playbook (outpatient) — Exclude secondary causes, confirm true hyperprolactinemia, image, start dopamine agonist first-line, restore gonadal axis, protect bone (Endo Soc 2011; Pituitary Soc 2023)
5. discontinue/substitute offending drug or treat hypothyroidism per culprit; levothyroxine titrated to TSH PO as indicated — Secondary cause identified (Treat the reversible cause before labelling a prolactinoma (Endo Soc 2011))
6. cabergoline 0.25–0.5 mg twice weekly, titrate PO twice weekly — Symptomatic micro/macroprolactinoma after exclusions (Preferred first-line DA — normalises PRL, shrinks tumour, restores gonadal axis (Pituitary Soc 2023))
7. bromocriptine 1.25 mg qHS, titrate to 2.5–7.5 mg/day PO daily–TID — Pregnancy planned or cabergoline-intolerant (Most pregnancy safety data (Endo Soc 2011))
8. estrogen/progestin or testosterone physiologic replacement PO/transdermal/IM per regimen — Persistent hypogonadism or observed microadenoma (Bone and gonadal protection if DA not used/effective (Endo Soc 2011))

Non-pharmacologic actions:
- Dedicated pituitary MRI (Endo Soc 2011)
- Formal visual field testing for macroadenoma (Pituitary Soc 2023)
- Referral to pituitary surgery centre if DA-resistant/intolerant (Pituitary Soc 2023)
- Preconception counselling; switch to bromocriptine if pregnancy planned (Endo Soc 2011)
- DEXA + calcium/vitamin D if hypogonadal/untreated (Endo Soc 2011)

AVOID / contraindication checks:
- Cabergoline cumulative dose echocardiographic valvulopathy surveillance (Parkinson derived caution; lower prolactinoma dose risk debated) (Pituitary Soc 2023)
- Dopamine agonist psychiatric and impulse control disorder screening and caution (Endo Soc 2011)
- Bromocriptine preferred over cabergoline when pregnancy planned (most safety data) (Endo Soc 2011)
- Do not stop antipsychotic without psychiatry — manage drug induced hyperprolactinemia collaboratively (Endo Soc 2011)
- Avoid routine prolactin measurement during pregnancy (physiologic rise confounds) (Endo Soc 2011)
- DA induced rapid macroadenoma shrinkage can unmask CSF rhinorrhoea — counsel and monitor (Pituitary Soc 2023)

Monitoring

Regimen monitoring:
- serum prolactin ~1 month after each dose change then periodically (Endo Soc 2011)
- pituitary MRI at ~1 year (sooner for macro / non-response / new symptoms) (Pituitary Soc 2023)
- formal visual fields baseline + surveillance for macroadenoma (Endo Soc 2011)
- echocardiography if high cumulative cabergoline dose or murmur (Pituitary Soc 2023)
- DEXA bone density if untreated or persistently hypogonadal (Endo Soc 2011)
- psychiatric and impulse-control screening at each DA visit (Endo Soc 2011)

Setting (outpatient) monitoring:
- Serum PRL ~1 month after dose change then periodically (Endo Soc 2011)
- MRI ~1 year or sooner for macro/non-response (Pituitary Soc 2023)
- Visual fields for macroadenoma; echocardiography if high cumulative cabergoline (Pituitary Soc 2023)
- Impulse-control / psychiatric screen at each DA visit (Endo Soc 2011)

Follow-up plan: Endocrinology long-term; consider DA taper/withdrawal trial after ≥2 years of normoprolactinemia + marked tumour shrinkage with surveillance; preconception counselling; bone health; symptom/return precautions (visual change, severe headache, galactorrhoea recurrence) (Endo Soc 2011; Pituitary Soc 2023)
- Close-out criterion: Long-term surveillance + withdrawal/pregnancy plan booked

Monitoring phase: Serum PRL ~1 month after dose change then periodically; MRI at ~1 year (sooner for macro / new symptoms / non-response); formal visual fields for macroadenoma; echocardiography if high cumulative cabergoline dose; DEXA if untreated/hypogonadal; psychiatric/impulse-control screening on DA (Endo Soc 2011; Pituitary Soc 2023)

Disposition

Current setting: outpatient — Exclude secondary causes, confirm true hyperprolactinemia, image, start dopamine agonist first-line, restore gonadal axis, protect bone (Endo Soc 2011; Pituitary Soc 2023)

Disposition criteria:
- Continue outpatient endocrinology if biochemically/clinically controlled (Endo Soc 2011)
- Admit/refer if apoplexy, acute visual loss, CSF leak, or severe DA adverse event (Pituitary Soc 2023)

Escalation triggers (move to higher acuity):
- Acute severe headache + visual loss / ophthalmoplegia → ED (apoplexy) (Pituitary Soc 2023)
- Rapidly progressive visual field loss → urgent neurosurgery (Pituitary Soc 2023)
- CSF rhinorrhoea on DA tumour shrinkage → ED + neurosurgery (Pituitary Soc 2023)
- Severe DA psychiatric decompensation / impulse-control crisis → psychiatry + stop DA (Endo Soc 2011)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Macroprolactinoma with acute severe headache + acute visual loss / ophthalmoplegia (pituitary apoplexy) (Pituitary Soc 2023)
- [LIFE_THREATENING] CSF rhinorrhoea after dopamine-agonist-induced rapid macroadenoma shrinkage (Pituitary Soc 2023)
- [SEVERE] Severe dopamine-agonist impulse-control disorder (pathological gambling/hypersexuality) or new psychosis (Endo Soc 2011)

Citations

- 2011 Endocrine Society Hyperprolactinemia Guideline (Melmed) + Pituitary Society prolactinoma consensus 2023/2024; 2021-2025 updates [PMID:21296991](https://pubmed.ncbi.nlm.nih.gov/21296991/)
- Cited evidence (PMID 37670148) [PMID:37670148](https://pubmed.ncbi.nlm.nih.gov/37670148/)
- Cited evidence (PMID 25421155) [PMID:25421155](https://pubmed.ncbi.nlm.nih.gov/25421155/)
- Cited evidence (PMID 14627787) [PMID:14627787](https://pubmed.ncbi.nlm.nih.gov/14627787/)

Last reconciled with current guidelines: 2026-05-22.
References
  • 2011 Endocrine Society Hyperprolactinemia Guideline (Melmed) + Pituitary Society prolactinoma consensus 2023/2024; 2021-2025 updates — PMID:21296991
  • Cited evidence (PMID 37670148) — PMID:37670148
  • Cited evidence (PMID 25421155) — PMID:25421155
  • Cited evidence (PMID 14627787) — PMID:14627787